Clinical trial
Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial…
NCT00034307 · ICOS-Texas Biotechnology, Industry · Unknown status
Key facts
| NCT number | NCT00034307 |
|---|---|
| Title | Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension |
| Lead sponsor | ICOS-Texas Biotechnology, Industry |
| Collaborators | ICOS Corporation Industry Texas Biotechnology Corporation |
| Status | Unknown status |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Hypertension |
| Intervention type | Drug |
| Interventions | sitaxsentan sodium |
| Enrollment | 180 |
| First posted | Apr 25, 2002 |
| Last update posted | Jun 24, 2005 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: